Collectively, these findings revealed a previously unrecognized metabolic axis linking SDH activity to the de novo synthesis of both purines and pyrimidines, while functional assays demonstrated that SDHA loss or pharmacological inhibition leads to growth defects across diverse cancer models. This evidence concerns the gene SDHB and cancer.